中国吉利德专利

StephenW

China Gilead patent

Following a patent challenge by I-MAK, Gilead Sciences has withdrawn a patent claim on the base compound for the direct-acting antiviral sofosbuvir. I-MAK says that the decision will allow manufacturers in China to produce generic versions of sofosbuvir from 2019. Sofosbuvir is currently marketed by Gilead in China at a cost of $8939 per treatment course but generic versions of the drug are already available for less than $100. I-MAK says that the decision will permit expansion of hepatitis C treatment in China where approximately 10 million people are estimated to have hepatitis C.

Jessica Burry of the MSF Access campaign said that as well as reducing the price in China, the decision would also allow Chinese manufacturers to supply the drug to other countries where this patent restriction does not apply.

StephenW

中国吉利德专利

在I-MAK的专利挑战之后，Gilead Sciences撤回了针对直接作用抗病毒sofosbuvir的基础化合物的专利权利要求。 I-MAK表示，该决定将允许中国制造商从2019年开始生产通用版本的sofosbuvir.Sofosbuvir目前由Gilead在中国销售，每个疗程的费用为8939美元，但该药物的仿制药价格已低于100美元。 I-MAK表示，该决定将允许在中国扩大丙型肝炎治疗，估计约有1000万人患有丙型肝炎。

MSF Access活动的Jessica Burry表示，除了降低中国的价格外，该决定还允许中国制造商向不适用该专利限制的其他国家供应该药物。

齐欢畅

，该决定将允许中国制造商从2019年开始生产通用版本的sofosbuvir.Sofosbuvir目前由Gilead在中国销售，每个疗程的费用为8939美元，但该药物的仿制药价格已低于100美元。 I-MAK表示，该决定将允许在中国扩大丙型肝炎治疗，估计约有1000万人患有丙型肝炎。